Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective: Hepatic stellate cells (HSC) transdifferentiation into myofibroblasts is central to fibrogenesis. Epigenetic mechanisms, including histone and DNA methylation, play a key role in this process. Concerted action between histone and DNA-mehyltransferases like G9a and DNMT1 is a common theme in gene expression regulation. We aimed to study the efficacy of CM272, a first-in-class dual and reversible G9a/DNMT1 inhibitor, in halting fibrogenesis. Design: G9a and DNMT1 were analysed in cirrhotic human livers, mouse models of liver fibrosis and cultured mouse HSC. G9a and DNMT1 expression was knocked down or inhibited with CM272 in human HSC (hHSC), and transcriptomic responses to transforming growth factor-β1 (TGFβ1) were examined. Glycolytic metabolism and mitochondrial function were analysed with Seahorse-XF technology. Gene expression regulation was analysed by chromatin immunoprecipitation and methylation-specific PCR. Antifibrogenic activity and safety of CM272 were studied in mouse chronic CCl 4 administration and bile duct ligation (BDL), and in human precision-cut liver slices (PCLSs) in a new bioreactor technology. Results: G9a and DNMT1 were detected in stromal cells in areas of active fibrosis in human and mouse livers. G9a and DNMT1 expression was induced during mouse HSC activation, and TGFβ1 triggered their chromatin recruitment in hHSC. G9a/DNMT1 knockdown and CM272 inhibited TGFβ1 fibrogenic responses in hHSC. TGFβ1-mediated profibrogenic metabolic reprogramming was abrogated by CM272, which restored gluconeogenic gene expression and mitochondrial function through on-target epigenetic effects. CM272 inhibited fibrogenesis in mice and PCLSs without toxicity. Conclusions: Dual G9a/DNMT1 inhibition by compounds like CM272 may be a novel therapeutic strategy for treating liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
DNA methylation pathways and their crosstalk with histone methylation
Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4043 · Cited by 1,000 · cited 2×
“20 21 This has been demonstrated for G9a, which physically and functionally interacts with DNMT1 driving tumour cell proliferation and adaptation to hypoxia, among other cancer traits.”
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis
Xie, N., Tan, Z., Banerjee, S., Cui, H., Ge, J., Liu, R.-M., Bernard, K., Thannickal, V. J., & Liu, G. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0780oc · Cited by 582
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate
Pacold, M. E., Brimacombe, K. R., Chan, S. H., Rohde, J. M., Lewis, C. A., Swier, L. J. Y. M., Possemato, R., Chen, W. W., Sullivan, L. B., Fiske, B. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2070 · Cited by 553 · cited 2×
“Noteworthy, the serine–glycine metabolic pathway is indeed important for the activation of LX2 cells, as indicated by the inhibitory effects of NCT503, a PHGDH enzymatic inhibitor, 42 on hypoxia-elicited growth and TGF β 1-induced collagen synthesis in these cells (online supplementary figure S8B).”
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., et al. (2014) · Nature · doi:10.1038/nature13557 · Cited by 535 · cited 1×
“46 Moreover, FBP1-mediated suppression of HIF-1 α activity may also be involved in the antagonistic effects of CM272 on TGF β 1 responses, as the HIF-1 α pathway is co-opted by TGF β 1 for its pro-fibrogenic activity even under normoxia.”
Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397
Self-citation
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“A growing list of epigenetic modifications regulating stellate cell activation has been uncovered (Barcena-Varela et al., 2021; Eslam et al., 2018; Schuppan et al., 2018).”
BackgroundThe Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
Rho, H., Terry, A. R., Chronis, C., & Hay, N. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.013 · Cited by 404
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
“Indeed, fibrogenesis is a key contributor to HCC development, and dysregulation of epigenetic circuits is central to liver fibrogenic cell activation and HCC progression.164,165 Pharmacological interference with such circuits is therefore emerging as an alternative strategy to halt liver fibrosis, and ultimately HCC d…”
BackgroundSelf-citation
Metadata
- Authors
- Barcena-Varela, M., Paish, H., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaria, E., Recalde, M., Garate, M., Claveria, A., Colyn, L., Arechederra, M., Iraburu, M. J., Milkiewicz, M., Milkiewicz, P., Sangro, B., Robinson, S. M., French, J., Pardo-Saganta, A., Oyarzabal, J., Prosper, F., Rombouts, K., Oakley, F., Mann, J., Berasain, C., Avila, M. A., & G Fernandez-Barrena, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2020-04-23
- Volume
- 70
- Issue
- 2
- Pages
- 388-400
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W3018009816
- Cited by
- 93
- References
- 15
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. https://app.cochat.ai/papers/10.1136/gutjnl-2019-320205
- The paper
- Barcena-Varela, M., Paish, H., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaria, E., Recalde, M., Garate, M., Claveria, A., Colyn, L., Arechederra, M., Iraburu, M. J., Milkiewicz, M., Milkiewicz, P., Sangro, B., Robinson, S. M., French, J., Pardo-Saganta, A., Oyarzabal, J., . . . G Fernandez-Barrena, M. (2021). Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut. https://doi.org/10.1136/gutjnl-2019-320205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.